The point of no return for Merrimack? Cancer drug developer axes yet another drug and more staff
Merrimack just can’t catch a break.
On Thursday, the company said it was abandoning its experimental drug, MM-310, after an early-stage study involving patients with solid tumors showed that treatment with the drug was cumulatively toxic to patients, despite trial protocol amendments.
As a result, the company said it was cutting jobs, but did not specify how many. It now has two preclinical drugs — MM-401 and MM-201 — left in its arsenal.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.